Mifomelatide (INNTooltip International Nonproprietary Name; developmental code name TCMCB07) is a melanocortin MC3 and MC4 receptor antagonist which is under development for the treatment of cachexia.

[1][2][3][4] It is a synthetic cyclic peptide and is taken by subcutaneous injection.

[1][3] Mifomelatide crosses the blood–brain barrier.

[3][4] The drug is being developed by Endevica Bio.

[1][2] As of February 2025, it is in phase 2 clinical trials.